Novartis: A mixed set of quarterly numbers

News published on October Tuesday 22, 2013
Share on

As expected, Novartis has delivered a mixed set of quarterly figures this morning. Total revenues stood at USD14.338bn up 6% in constant currencies, driven by a decent performance in Pharma and for Alcon, good growth at Sandoz and an ongoing recovery in Consumer Healthcare. Currencies dented the reported growth rate by 2pp. Note the healthy performance in emerging markets (+9%) including China (+18%). Core operating margin was not so good, narrowing by 230bp with a clear decrease for both Pharma (very high R&D expenses) and Alcon, also under pressure from currencies. Since generic Diovan monotherapy is still out of the radar screen, full-year guidance has again been increased, this time crossing into positive territory for Core operating profit.

Full report available to subscribers

Please contact  

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities